Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2001 May;60(5):459–466. doi: 10.1136/ard.60.5.459

Prevalence and clinical significance of antikeratin antibodies and other serological markers in Lithuanian patients with rheumatoid arthritis

L Vasiliauskiene 1, A Wiik 1, M Hoier-Madsen 1
PMCID: PMC1753650  PMID: 11302867

Abstract

OBJECTIVES—To assess the clinical value of several serological markers in Lithuanian patients with rheumatoid arthritis (RA) compared with control patients with rheumatic disease and age matched healthy controls.
METHODS—Serum samples from 96 patients with RA of approximately 8 years' duration, 90 rheumatic disease controls, and 37 healthy subjects were tested. Antikeratin antibody (AKA), antineutrophil cytoplasmic antibody (ANCA), and antinuclear antibody (ANA) titres were estimated by indirect immunofluorescence (IIF) and serum samples positive for ANA and ANCA were further studied by enzyme linked immunosorbent assay (ELISA). IgA and IgM rheumatoid factors (RF) were measured by ELISA.
RESULTS—A positive AKA test was highly specific for RA (diagnostic specificity 97%), being found in 44% of the patients. Although both RF tests had a higher sensitivity, they were less specific for RA. ANCA was detected in 33% of patients with RA but lacked diagnostic specificity. AKA and ANCA were associated with more erosive disease and the presence of extra-articular manifestations. Positivity for AKA, IgA RF, and ANCA was significantly associated with disease activity and worse functional capacity. However, in multiple regression analysis only positivity for AKA was significantly correlated with functional disability (p=0.0001), evaluated by the Steinbrocker functional classification, and no single marker had any relation with radiological damage.
CONCLUSION—Although AKA showed the highest disease specificity, all serological markers studied except ANA exhibited interesting associations with important clinical and paraclinical parameters of RA.



Full Text

The Full Text of this article is available as a PDF (180.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Afeltra A., Sebastiani G. D., Galeazzi M., Caccavo D., Ferri G. M., Marcolongo R., Bonomo L. Antineutrophil cytoplasmic antibodies in synovial fluid and in serum of patients with rheumatoid arthritis and other types of synovitis. J Rheumatol. 1996 Jan;23(1):10–15. [PubMed] [Google Scholar]
  2. Anderson S. G., Bentzon M. W., Houba V., Krag P. International reference preparation of rheumatoid arthritis serum. Bull World Health Organ. 1970;42(2):311–318. [PMC free article] [PubMed] [Google Scholar]
  3. Arnett F. C., Edworthy S. M., Bloch D. A., McShane D. J., Fries J. F., Cooper N. S., Healey L. A., Kaplan S. R., Liang M. H., Luthra H. S. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988 Mar;31(3):315–324. doi: 10.1002/art.1780310302. [DOI] [PubMed] [Google Scholar]
  4. Cambridge G., Williams M., Leaker B., Corbett M., Smith C. R. Anti-myeloperoxidase antibodies in patients with rheumatoid arthritis: prevalence, clinical correlates, and IgG subclass. Ann Rheum Dis. 1994 Jan;53(1):24–29. doi: 10.1136/ard.53.1.24. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Coremans I. E., Hagen E. C., Daha M. R., van der Woude F. J., van der Voort E. A., Kleijburg-van der Keur C., Breedveld F. C. Antilactoferrin antibodies in patients with rheumatoid arthritis are associated with vasculitis. Arthritis Rheum. 1992 Dec;35(12):1466–1475. doi: 10.1002/art.1780351210. [DOI] [PubMed] [Google Scholar]
  6. Fouquet B., Renoux M., Eveleich M. C., Bardos P., Valat J. P. Facteurs rhumatoïdes. Isotypes et sévérité de la polyarthrite rhumatoïde. Rev Rhum Mal Osteoartic. 1987 Jan;54(1):31–35. [PubMed] [Google Scholar]
  7. Gioud-Paquet M., Auvinet M., Raffin T., Girard P., Bouvier M., Lejeune E., Monier J. C. IgM rheumatoid factor (RF), IgA RF, IgE RF, and IgG RF detected by ELISA in rheumatoid arthritis. Ann Rheum Dis. 1987 Jan;46(1):65–71. doi: 10.1136/ard.46.1.65. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Hajiroussou V. J., Skingle J., Gillett A. P., Webley M. Significance of antikeratin antibodies in rheumatoid arthritis. J Rheumatol. 1985 Feb;12(1):57–59. [PubMed] [Google Scholar]
  9. Heegaard N. H., Brimnes J. Comparison of heparin-binding to lactoferrin from human milk and from human granulocytes by means of affinity capillary electrophoresis. Electrophoresis. 1996 Dec;17(12):1916–1920. doi: 10.1002/elps.1150171218. [DOI] [PubMed] [Google Scholar]
  10. Heegaard N. H., Jakobsen D. R., Klattschou D. Purification of Wegener's granulomatosis autoantigen, proteinase 3, from neutrophils by Triton X-114 extraction of azurophilic granules. Anal Biochem. 1997 Nov 15;253(2):259–262. doi: 10.1006/abio.1997.2374. [DOI] [PubMed] [Google Scholar]
  11. Houssien D. A., Jónsson T., Davies E., Scott D. L. Rheumatoid factor isotypes, disease activity and the outcome of rheumatoid arthritis: comparative effects of different antigens. Scand J Rheumatol. 1998;27(1):46–53. doi: 10.1080/030097498441173. [DOI] [PubMed] [Google Scholar]
  12. Høier-Madsen M., Andersen M. G. Mikrohaemagglutinationstest til undersøgelse for antistoffer mod extractable nuclear antigen (ENA). Sammenlignende undersøgelser af forskellige patientgrupper for ANA, DNA- og ENA-antistoffer. Ugeskr Laeger. 1980 Sep 29;142(40):2627–2630. [PubMed] [Google Scholar]
  13. Høier-Madsen M., Nielsen L. P., Møller S. Bestemmelse af IgM-rheumafaktorer ved enzyme-linked immunosorbent assay (ELISA). Ugeskr Laeger. 1986 Aug 4;148(32):2018–2021. [PubMed] [Google Scholar]
  14. Johnson G. D., Carvalho A., Holborow E. J., Goddard D. H., Russell G. Antiperinuclear factor and keratin antibodies in rheumatoid arthritis. Ann Rheum Dis. 1981 Jun;40(3):263–266. doi: 10.1136/ard.40.3.263. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Jorgensen C., Legouffe M. C., Bologna C., Brochier J., Sany J. IgA isotype rheumatoid factor in rheumatoid arthritis: clinical implications. Clin Exp Rheumatol. 1996 May-Jun;14(3):301–304. [PubMed] [Google Scholar]
  16. Kirstein H., Mathiesen F. K. Antikeratin antibodies in rheumatoid arthritis. Methods and clinical significance. Scand J Rheumatol. 1987;16(5):331–338. doi: 10.3109/03009748709102504. [DOI] [PubMed] [Google Scholar]
  17. Kroot E. J., de Jong B. A., van Leeuwen M. A., Swinkels H., van den Hoogen F. H., van't Hof M., van de Putte L. B., van Rijswijk M. H., van Venrooij W. J., van Riel P. L. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum. 2000 Aug;43(8):1831–1835. doi: 10.1002/1529-0131(200008)43:8<1831::AID-ANR19>3.0.CO;2-6. [DOI] [PubMed] [Google Scholar]
  18. Kurki P., Aho K., Palosuo T., Heliövaara M. Immunopathology of rheumatoid arthritis. Antikeratin antibodies precede the clinical disease. Arthritis Rheum. 1992 Aug;35(8):914–917. doi: 10.1002/art.1780350810. [DOI] [PubMed] [Google Scholar]
  19. Mageed R. A., Kirwan J. R., Thompson P. W., McCarthy D. A., Holborow E. J. Characterisation of the size and composition of circulating immune complexes in patients with rheumatoid arthritis. Ann Rheum Dis. 1991 Apr;50(4):231–236. doi: 10.1136/ard.50.4.231. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Mallya R. K., Young B. J., Pepys M. B., Hamblin T. J., Mace B. E., Hamilton E. B. Anti-keratin antibodies in rheumatoid arthritis: frequency and correlation with other features of the disease. Clin Exp Immunol. 1983 Jan;51(1):17–20. [PMC free article] [PubMed] [Google Scholar]
  21. Mulder A. H., Horst G., van Leeuwen M. A., Limburg P. C., Kallenberg C. G. Antineutrophil cytoplasmic antibodies in rheumatoid arthritis. Characterization and clinical correlations. Arthritis Rheum. 1993 Aug;36(8):1054–1060. doi: 10.1002/art.1780360805. [DOI] [PubMed] [Google Scholar]
  22. Mustila A., Korpela M., Mustonen J., Helin H., Huhtala H., Soppi E., Pasternack A., Miettinen A. Perinuclear antineutrophil cytoplasmic antibody in rheumatoid arthritis: a marker of severe disease with associated nephropathy. Arthritis Rheum. 1997 Apr;40(4):710–717. doi: 10.1002/art.1780400417. [DOI] [PubMed] [Google Scholar]
  23. Mustila A., Paimela L., Leirisalo-Repo M., Huhtala H., Miettinen A. Antineutrophil cytoplasmic antibodies in patients with early rheumatoid arthritis: an early marker of progressive erosive disease. Arthritis Rheum. 2000 Jun;43(6):1371–1377. doi: 10.1002/1529-0131(200006)43:6<1371::AID-ANR22>3.0.CO;2-R. [DOI] [PubMed] [Google Scholar]
  24. NIENHUIS R. L., MANDEMA E. A NEW SERUM FACTOR IN PATIENTS WITH RHEUMATOID ARTHRITIS; THE ANTIPERINUCLEAR FACTOR. Ann Rheum Dis. 1964 Jul;23:302–305. doi: 10.1136/ard.23.4.302. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Olsson I., Olofsson T., Odeberg H. Myeloperoxidase-mediated iodination in granulocytes. Scand J Haematol. 1972;9(5):483–491. doi: 10.1111/j.1600-0609.1972.tb00974.x. [DOI] [PubMed] [Google Scholar]
  26. Ordeig J., Guardia J. Diagnostic value of antikeratin antibodies in rheumatoid arthritis. J Rheumatol. 1984 Oct;11(5):602–604. [PubMed] [Google Scholar]
  27. Paimela L., Gripenberg M., Kurki P., Leirisalo-Repo M. Antikeratin antibodies: diagnostic and prognostic markers for early rheumatoid arthritis. Ann Rheum Dis. 1992 Jun;51(6):743–746. doi: 10.1136/ard.51.6.743. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Röther E., Schochat T., Peter H. H. Antineutrophil cytoplasmic antibodies (ANCA) in rheumatoid arthritis: a prospective study. Rheumatol Int. 1996;15(6):231–237. doi: 10.1007/BF00290376. [DOI] [PubMed] [Google Scholar]
  29. Savige J. A., Gallicchio M. C., Stockman A., Cunningham T. J., Rowley M. J., Georgiou T., Davies D. Anti-neutrophil cytoplasm antibodies in rheumatoid arthritis. Clin Exp Immunol. 1991 Oct;86(1):92–98. doi: 10.1111/j.1365-2249.1991.tb05779.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Schellekens G. A., Visser H., de Jong B. A., van den Hoogen F. H., Hazes J. M., Breedveld F. C., van Venrooij W. J. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum. 2000 Jan;43(1):155–163. doi: 10.1002/1529-0131(200001)43:1<155::AID-ANR20>3.0.CO;2-3. [DOI] [PubMed] [Google Scholar]
  31. Schellekens G. A., de Jong B. A., van den Hoogen F. H., van de Putte L. B., van Venrooij W. J. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest. 1998 Jan 1;101(1):273–281. doi: 10.1172/JCI1316. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Scott D. L., Delamere J. P., Jones L. J., Walton K. W. Significance of laminar antikeratin antibodies to rat oesophagus in rheumatoid arthritis. Ann Rheum Dis. 1981 Jun;40(3):267–271. doi: 10.1136/ard.40.3.267. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Sebbag M., Simon M., Vincent C., Masson-Bessière C., Girbal E., Durieux J. J., Serre G. The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies. J Clin Invest. 1995 Jun;95(6):2672–2679. doi: 10.1172/JCI117969. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Sharp G. C., Irvin W. S., Tan E. M., Gould R. G., Holman H. R. Mixed connective tissue disease--an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med. 1972 Feb;52(2):148–159. doi: 10.1016/0002-9343(72)90064-2. [DOI] [PubMed] [Google Scholar]
  35. Shmerling R. H., Delbanco T. L. The rheumatoid factor: an analysis of clinical utility. Am J Med. 1991 Nov;91(5):528–534. doi: 10.1016/0002-9343(91)90190-9. [DOI] [PubMed] [Google Scholar]
  36. Tan E. M. Autoantibodies to nuclear antigens (ANA): their immunobiology and medicine. Adv Immunol. 1982;33:167–240. doi: 10.1016/s0065-2776(08)60836-6. [DOI] [PubMed] [Google Scholar]
  37. Tan E. M., Feltkamp T. E., Smolen J. S., Butcher B., Dawkins R., Fritzler M. J., Gordon T., Hardin J. A., Kalden J. R., Lahita R. G. Range of antinuclear antibodies in "healthy" individuals. Arthritis Rheum. 1997 Sep;40(9):1601–1611. doi: 10.1002/art.1780400909. [DOI] [PubMed] [Google Scholar]
  38. Teitsson I., Withrington R. H., Seifert M. H., Valdimarsson H. Prospective study of early rheumatoid arthritis. I. Prognostic value of IgA rheumatoid factor. Ann Rheum Dis. 1984 Oct;43(5):673–678. doi: 10.1136/ard.43.5.673. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Vejtorp M., Høier-Madsen M., Halberg P. Enzyme-linked immunosorbent assay for determination of IgM rheumatoid factor. Scand J Rheumatol. 1979;8(2):65–70. doi: 10.3109/03009747909105338. [DOI] [PubMed] [Google Scholar]
  40. Vincent C., Serre G., Lapeyre F., Fournié B., Ayrolles C., Fournié A., Soleilhavoup J. P. High diagnostic value in rheumatoid arthritis of antibodies to the stratum corneum of rat oesophagus epithelium, so-called 'antikeratin antibodies'. Ann Rheum Dis. 1989 Sep;48(9):712–722. doi: 10.1136/ard.48.9.712. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Vincent C., de Keyser F., Masson-Bessière C., Sebbag M., Veys E. M., Serre G. Anti-perinuclear factor compared with the so called "antikeratin" antibodies and antibodies to human epidermis filaggrin, in the diagnosis of arthritides. Ann Rheum Dis. 1999 Jan;58(1):42–48. doi: 10.1136/ard.58.1.42. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Wiik A., Jensen E., Friis J. Granulocyte-specific antinuclear factors in synovial fluids and sera from patients with rheumatoid arthritis. Ann Rheum Dis. 1974 Nov;33(6):515–522. doi: 10.1136/ard.33.6.515. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Youinou P., Le Goff P., Colaco C. B., Thivolet J., Tater D., Viac J., Shipley M. Antikeratin antibodies in serum and synovial fluid show specificity for rheumatoid arthritis in a study of connective tissue diseases. Ann Rheum Dis. 1985 Jul;44(7):450–454. doi: 10.1136/ard.44.7.450. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Young B. J., Mallya R. K., Leslie R. D., Clark C. J., Hamblin T. J. Anti-keratin antibodies in rheumatoid arthritis. Br Med J. 1979 Jul 14;2(6182):97–99. doi: 10.1136/bmj.2.6182.97. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. van Zeben D., Hazes J. M., Zwinderman A. H., Cats A., van der Voort E. A., Breedveld F. C. Clinical significance of rheumatoid factors in early rheumatoid arthritis: results of a follow up study. Ann Rheum Dis. 1992 Sep;51(9):1029–1035. doi: 10.1136/ard.51.9.1029. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES